Skip to main content
SpringerLink
Log in

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

References

  1. Li CF, Wang J, Huang W, Hou C, Chou S, Eng JH, Lin C, Yu S, Huang H (2008) Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol 32:587–599

    Article  PubMed  Google Scholar 

  2. Cassier JA, Blay JY et al (2012) Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118(6):1649–1655

    Article  PubMed  CAS  Google Scholar 

  3. Somerhausen N, Fletcher C (2000) Diffuse-type giant cell tumor clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Path 24(4):479–492

    Article  PubMed  CAS  Google Scholar 

  4. Ravi V, Wang W, Lewis VO (2011) Treatment of tenosynovial giant cell tumor and pigmented villondular synovitis. Curr Opin Oncol 23:361–366

    Article  PubMed  CAS  Google Scholar 

  5. Chin KR, Barr SJ, Winalski C et al (2002) Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 84-A:2192–2202

    PubMed  Google Scholar 

  6. Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielson TO (2010) Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma. doi:10.1155/2010/174528

  7. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215–244

    Article  PubMed  CAS  Google Scholar 

  8. Giustina A, Mazziotti G, Canalis E (2006) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559

    Article  CAS  Google Scholar 

  9. Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheem EM, Backer JM, White MF (1993) IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3′-kinase. Endocrinology 132:1421–1430

    PubMed  CAS  Google Scholar 

  10. Raile K, Höflich A, Kessler U et al (1994) Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 159(3):531–541

    Article  PubMed  CAS  Google Scholar 

  11. Burrow S, Andrulis IL, Pollak M, Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Onc 69:21–27

    Article  CAS  Google Scholar 

  12. Steigen SE, Schaeffer DF, West RB, Nielsen TO (2009) Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Modern Path 22:914–921

    Article  CAS  Google Scholar 

  13. Pollack MN, Polychronakos C, Richard M (1990) Insulin-like growth factor-I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82:301–305

    Article  Google Scholar 

  14. Wang Y, Lipari P, Wang X et al (2010) A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 9:410

    Article  PubMed  CAS  Google Scholar 

  15. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclo nal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800–5807

    Article  PubMed  CAS  Google Scholar 

  16. Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase I expansion cohort study. Lancet Oncol 11(2):129–135

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Papp AS, Patel S, Crowley J et al (2010) Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): results of a phase II SARC study. J Clin Oncol 28:15s

    Google Scholar 

  18. Mita MM, Tolcher AW (2007) The role of mTOR inhibitors for treatment of sarcomas. Curr Onc Rep 9:316–322

    Article  CAS  Google Scholar 

  19. Dumez H (2008) A phase I–II study of everoilmus (RAD001) in combination with imatinib in patients with imatinib resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 21(10):1990–1998

    Google Scholar 

  20. Chawla SP, Blay J, Ray-Coquard IL, Cesne AL, Staddon AP, et al. (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29 (suppl; abstr 10005)

  21. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  22. Quek R, Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871–879

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Author notes

  1. Monica Mita

    Present address: Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SCCT Mezzanine MS 35, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA

Authors and Affiliations

  1. Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SCCT Mezzanine MS 35, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA

    Swati Sikaria & Monica Mita

  2. Department of Pathology, The Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA

    Josefine Heim-Hall

  3. Medical Oncology, The Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA

    Elizabeth H. Diaz, Kamelesh Sankhala, Brenda Laabs & Monica Mita

  4. Orthopedic Surgery, The Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA

    Ronald Williams

Authors
  1. Swati Sikaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josefine Heim-Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth H. Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kamelesh Sankhala
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brenda Laabs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Monica Mita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica Mita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sikaria, S., Heim-Hall, J., Diaz, E.H. et al. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Targ Oncol 9, 73–79 (2014). https://doi.org/10.1007/s11523-013-0267-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-013-0267-8

Keywords

Search

Navigation